The median serum concentrations of visfatin were significantly lower in the COVID-19 patients than in the control group for visfatin 1 [4.29 ng/mL, (3.0–6.88 ng/mL) vs. 37.16 ng/mL (24.74–50.12 ng/mL), p < 0.001] and significantly higher for visfatin 2 [52.05 ng/mL, (31.2–69.66 ng/mL) vs. 37.16 ng/mL (24.74–50.12 ng/mL), p = 0.048]. Here, NAMPT is linked to COVID-19.